Radioiodine Treatment of Hyperthyroidism—Prognostic Factors for Outcome
Authors:
- 1 August 2001
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 86 (8) , 3611-3617
Abstract
There is little consensus regarding the most appropriate dose regimen for radioiodine (131I) in the treatment of hyperthyroidism. We audited 813 consecutive hyperthyroid patients treated with radioiodine to compare the efficacy of 2 fixed-dose regimens used within our center (185 megabequerels, 370 megabequerels) and to explore factors that may predict outcome. Patients were categorized into 3 diagnostic groups: Graves’ disease, toxic nodular goiter, and hyperthyroidism of indeterminate etiology. Cure after a single dose of 131I was investigated and defined as euthyroid off all treatment for 6 months or T4 replacement for biochemical hypothyroidism in all groups. As expected, patients given a single dose of 370 megabequerels had a higher cure rate than those given 185 megabequerels, (84.6% vs. 66.6%, P < 0.0001) but an increase in hypothyroidism incidence at 1 yr (60.8% vs. 41.3%, P < 0.0001). There was no difference in cure rate between the groups with Graves’ disease and those with toxic nodular goiter (69.5% vs. 71.4%; P, not significant), but Graves’ patients had a higher incidence of hypothyroidism (54.5% vs. 31.7%, P< 0.0001). Males had a lower cure rate than females (67.6% vs. 76.7%, P = 0.02), whereas younger patients (<40 yr) had a lower cure rate than patients over 40 yr old (68.9% vs. 79.3%, P < 0.001). Patients with more severe hyperthyroidism (P < 0.0001) and with goiters of medium or large size (P < 0.0001) were less likely to be cured after a single dose of 131I. The use of antithyroid drugs, during a period 2 wk before or after 131I, resulted in a significant reduction in cure rate in patients given 185 megabequerels 131I (P < 0.01) but not 370 megabequerels. Logistic regression analysis showed dose, gender, goiters of medium or large size, and severity of hyperthyroidism to be significant independent prognostic factors for cure after a single dose of 131I. We have demonstrated that a single fixed dose of 370 megabequerels 131I is highly effective in curing toxic nodular hyperthyroidism as well as Graves’ hyperthyroidism. Because male patients and those with more severe hyperthyroidism and medium or large-sized goiters are less likely to respond to a single dose of radioiodine, we suggest that the value of higher fixed initial doses of radioiodine should be evaluated in these patient categories with lower cure rates.Keywords
This publication has 27 references indexed in Scilit:
- Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcomeEuropean Journal of Endocrinology, 1999
- TREATMENT OF HYPERTHYROIDISM WITH RADIOACTIVE IODINEEndocrinology and Metabolism Clinics of North America, 1998
- Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?Clinical Endocrinology, 1995
- Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131 iodine activity*. Results from a prospective, randomized, multicentre studyEuropean Journal of Clinical Investigation, 1995
- The Management of HyperthyroidismNew England Journal of Medicine, 1994
- Long‐term follow‐up of treatment of thyrotoxicosis by three different methodsClinical Endocrinology, 1991
- OUTCOME FOLLOWING STANDARDIZED 185 MBq DOSE 131I THERAPY FOR GRAVES' DISEASEClinical Endocrinology, 1988
- Radioiodine therapy for Graves' disease: multivariate analysis of pretreatment parameters and early outcomeEuropean Journal of Nuclear Medicine and Molecular Imaging, 1985
- Low-Dose 131I in Treatment of Graves' DiseaseJournal of the Royal Society of Medicine, 1985
- Long-Term Follow-up Study of Compensated Low-Dose131I Therapy for Graves' DiseaseNew England Journal of Medicine, 1984